Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Perioperative PD-L1 Inhibition With Avelumab and Docetaxel, Cisplatin and 5-Fluorouracil for Resectable Locally Advanced Esophago-Gastric Adenocarcinoma

NCT03288350 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT03288350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Perioperative PD-L1 Inhibition With Avelumab and Docetaxel, Cisplatin and 5-Fluorouracil for Resectable Locally Advanced Esophago-Gastric Adenocarcinoma
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 2
Overall status
Unknown status
Start date
February 22, 2018
Completion date
December 31, 2023
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma